Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. With its scientific expertise, Medigene is working on the development of innovative immunotherapies such as T cell receptor-modified T cells (TCR‑Ts) or dendritic cell (DC) vaccines to treat cancer in fields of high medical need. The first product candidates are in clinical development.
Company Strategy
Medigene’s strategy is to develop its own therapies towards clinical proof-of-concept with the ultimate aim of advancing its technologies into development against solid cancers. In addition, the Company offers selected partners the opportunity to discover and develop additional therapies on the basis of its technological platforms.
Short Profile
- Focus on T-cell-directed immunotherapies
- TCR-T therapy MDG1011 in patients with acute myeloid leukemia (AML) or myelodisplastic syndrome (MDS) in clinical Phase I/II trial
- Completed clinical Phase I/II trial of DC vaccine in patients with AML
- Roughly 80 employees with expertise in immunotherapy and pharmaceutical development
- Headquartered in Martinsried near Munich (Germany), with US-office in San Diego, California
- Listed on Frankfurt Stock Exchange: MDG1; ISIN DE000A1X3W00
Company History
| Year | Milestone |
|---|---|
| 1994 | Medigene founded as Munich Gene Center spin-off |
| 2000 | Medigene IPO listed on the Frankfurt Stock Exchange |
| 2001 | Medigene acquired US biotechnology company NeuroVir, Inc. |
| 2004 | Medigene acquired products and technology of Munich Biotech AG |
| 2004 | Medigene received first regulatory approval for cancer drug Eligard® in Germany |
| 2006 | Medigene acquired British biotechnology company Avidex Limited |
| 2006 | Medigene’s product Veregen® became the first FDA-approved biopharmaceutical of a German biotech company in the USA |
| 2012-14 | Strategic repositioning through sale of Eligard®, EndoTAG® and RhuDex® |
| 2014 | Focus on immuno-oncology by strategic acquisition of Trianta Immunotherapies GmbH (renamed Medigene Immunotherapies GmbH) |
| 2015 | Start of Phase I/II clinical trial with DC vaccine (FDC101) to treat AML |
| 2015 | Amgen acquires Medigene spin-off Catherex |
| 2016 | Start of Phase II part of the clinical trial with DC vaccine (FDC101) |
| 2016 | bluebird bio and Medigene establish strategic T cell receptor alliance in cancer immunotherapy |
| 2017 | U.S.-rights for Veregen® are disposed |
| 2018 | Expansion of the bluebird bio partnership |
| 2018 | Start of the Phase I/II study of MDG1011 in AML and MDS |
| 2019 | Roivant and Sinovant launch Cytovant Sciences in partnership with Medigene to develop cellular therapies in Asia |
| 2019 | Sale of remaining rights and inventories of Veregen® |
| 2020 | Publication of topline data of the DC vaccine trial (FDC101) |
| 2021 | Publication of topline data of the Phase I/II study of MDG1011 in AML and MDS |
| 2022 | Comprehensive research and development partnership with BioNTech |